🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Duopharma Biotech Berhad (KLSE:DPHARMA)
Malaysia flag Malaysia · Delayed Price · Currency is MYR
1.030
-0.050 (-4.63%)
At close: Nov 20, 2026

Duopharma Biotech Berhad Statistics

Total Valuation

KLSE:DPHARMA has a market cap or net worth of MYR 990.80 million. The enterprise value is 1.18 billion.

Market Cap990.80M
Enterprise Value 1.18B

Important Dates

The next estimated earnings date is Tuesday, February 23, 2027.

Earnings Date Feb 23, 2027
Ex-Dividend Date Sep 3, 2026

Share Statistics

KLSE:DPHARMA has 961.94 million shares outstanding. The number of shares has decreased by -0.01% in one year.

Current Share Class 961.94M
Shares Outstanding 961.94M
Shares Change (YoY) -0.01%
Shares Change (QoQ) -0.05%
Owned by Insiders (%) 0.30%
Owned by Institutions (%) 66.52%
Float 529.68M

Valuation Ratios

The trailing PE ratio is 9.20 and the forward PE ratio is 9.18. KLSE:DPHARMA's PEG ratio is 0.79.

PE Ratio 9.20
Forward PE 9.18
PS Ratio 1.08
PB Ratio 1.24
P/TBV Ratio 1.29
P/FCF Ratio 12.59
P/OCF Ratio 9.78
PEG Ratio 0.79
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 5.97, with an EV/FCF ratio of 14.99.

EV / Earnings 10.97
EV / Sales 1.29
EV / EBITDA 5.97
EV / EBIT 7.45
EV / FCF 14.99

Financial Position

The company has a current ratio of 3.67, with a Debt / Equity ratio of 0.46.

Current Ratio 3.67
Quick Ratio 2.06
Debt / Equity 0.46
Debt / EBITDA 1.87
Debt / FCF 4.71
Interest Coverage 7.06

Financial Efficiency

Return on equity (ROE) is 13.93% and return on invested capital (ROIC) is 12.31%.

Return on Equity (ROE) 13.93%
Return on Assets (ROA) 7.61%
Return on Invested Capital (ROIC) 12.31%
Return on Capital Employed (ROCE) 13.57%
Weighted Average Cost of Capital (WACC) 5.87%
Revenue Per Employee 468,562
Profits Per Employee 54,988
Employee Count1,957
Asset Turnover 0.65
Inventory Turnover 1.65

Taxes

In the past 12 months, KLSE:DPHARMA has paid 33.68 million in taxes.

Income Tax 33.68M
Effective Tax Rate 23.84%

Stock Price Statistics

The stock price has decreased by -18.25% in the last 52 weeks. The beta is 0.38, so KLSE:DPHARMA's price volatility has been lower than the market average.

Beta (5Y) 0.38
52-Week Price Change -18.25%
50-Day Moving Average 1.13
200-Day Moving Average 1.25
Relative Strength Index (RSI) 33.15
Average Volume (20 Days) 293,805

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, KLSE:DPHARMA had revenue of MYR 916.98 million and earned 107.61 million in profits. Earnings per share was 0.11.

Revenue916.98M
Gross Profit 394.01M
Operating Income 158.34M
Pretax Income 141.30M
Net Income 107.61M
EBITDA 194.45M
EBIT 158.34M
Earnings Per Share (EPS) 0.11
Full Income Statement

Balance Sheet

The company has 181.20 million in cash and 370.68 million in debt, with a net cash position of -189.48 million or -0.20 per share.

Cash & Cash Equivalents 181.20M
Total Debt 370.68M
Net Cash -189.48M
Net Cash Per Share -0.20
Equity (Book Value) 801.14M
Book Value Per Share 0.83
Working Capital 558.73M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 101.29 million and capital expenditures -22.57 million, giving a free cash flow of 78.72 million.

Operating Cash Flow 101.29M
Capital Expenditures -22.57M
Depreciation & Amortization 36.11M
Net Borrowing -123.90M
Free Cash Flow 78.72M
FCF Per Share 0.08
Full Cash Flow Statement

Margins

Gross margin is 42.97%, with operating and profit margins of 17.27% and 11.74%.

Gross Margin 42.97%
Operating Margin 17.27%
Pretax Margin 15.41%
Profit Margin 11.74%
EBITDA Margin 21.21%
EBIT Margin 17.27%
FCF Margin 8.58%

Dividends & Yields

This stock pays an annual dividend of 0.05, which amounts to a dividend yield of 4.42%.

Dividend Per Share 0.05
Dividend Yield 4.42%
Dividend Growth (YoY) 30.00%
Years of Dividend Growth 2
Payout Ratio 40.67%
FCF Payout Ratio 55.60%
Buyback Yield 0.01%
Shareholder Yield 4.42%
Earnings Yield 10.87%
FCF Yield 7.95%
Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside
Graham Formula Value
Graham Formula Upside

Analyst Forecast

The average price target for KLSE:DPHARMA is 1.67, which is 61.75% higher than the current price. The consensus rating is "Strong Buy".

Price Target 1.67
Price Target Difference 61.75%
Analyst Consensus Strong Buy
Analyst Count 5
Revenue Growth Forecast (3Y) 2.46%
EPS Growth Forecast (3Y) 9.16%

Stock Splits

The last stock split was on September 6, 2021. It was a forward split with a ratio of 1.3333333333.

Last Split Date Sep 6, 2021
Split Type Forward
Split Ratio 1.3333333333

Scores

Altman Z-Score n/a
Piotroski F-Score 7